Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference (GlobeNewswire) - Nov 25, 2024 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "The safety profile through Cohort 5 was favorable, with 1 dose-limiting toxicity (thrombocytopenia) observed in Cohort 5; Median overall survival for Cohorts 1-4 was 9 months, with 6 out of the 16 patients alive at the time of analysis; Three of the 20 patients received up to 3 doses of Rhenium (186Re) Obisbemeda under compassionate use IND, all surviving over 400 days, with one exceeding 30 months; Cohort 6 is anticipated to conclude in Q1 2025; Planning is underway for a Phase 1b single dose expansion cohort trial using the Cohort 4 dose of 44 mCi, which is expected to fully enroll in 2025; Obtained agreement from FDA to begin the ReSPECT-LM multi-administration trial for patients with LM (IND 153715); enrollment is expected to begin in early 2025 at seven U.S. trial sites."
P1 data • Trial status • Brain Cancer • Oncology • Solid Tumor
|